1,040 results on '"Stilgenbauer"'
Search Results
2. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
3. Hypothalamic sex-specific metabolic shift by canagliflozin during aging
4. T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia
5. Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial
6. Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies
7. Hypothalamic Sex-Specific Metabolic Shift by Canagliflozin during Aging
8. Abstract P15: Cross-species DNA methylation profiling of T and B cell populations in T-PLL and B-CLL compared to TCL1 transgenic mouse models
9. Genetic alterations in chronic lymphocytic leukemia and plasma cell neoplasms – a practical guide to WHO HAEM5
10. Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care
11. SOP bowel dysfunction in palliative care medicine
12. An Updated Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) Versus Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
13. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
14. Selective (a)-L-Rhamnosylation and Neuroprotective Activity Exploration of Cardiotonic Steroids
15. Bombing of Urban Areas During World War II and the Bosnian War
16. Russia: Leningrad (St. Petersburg) and Stalingrad (Volgograd)
17. Sarajevo
18. Reconstruction of Urban Forests
19. Japan: Tokyo and Hiroshima
20. Germany: Hamburg and Dresden
21. Introduction
22. England: London and Coventry
23. Urban Forests Prior to World War II
24. Summary and Conclusions
25. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
26. Patterns of defeasible inference in causal diagnostic judgment
27. Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies
28. Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL
29. Microglial NF-κB Signaling Deficiency Protects Against Metabolic Disruptions Caused by Volatile Organic Compound via Modulating the Hypothalamic Transcriptome
30. Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
31. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
32. Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
33. Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics
34. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
35. Nucleosome repositioning in chronic lymphocytic leukemia
36. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
37. Detection of thyroid hormone transport inhibition in the Xenopus Eleutheroembryonic Thyroid Assay (XETA)
38. Aging Associates with Cilium Elongation and Dysfunction in Kidney and Pancreas
39. S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
40. P614: NOVEL SPLICE-SITE MUTATION IN PLCG2 ASSOCIATED WITH RESISTANCE TO BTK INHIBITORS
41. S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
42. P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
43. P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
44. Lipophilic Fe(III)-Complex with Potent Broad-Spectrum Anticancer Activity and Ability to Overcome Pt Resistance in A2780cis Cancer Cells
45. Richter transformation: epigenetics to blame?
46. A PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX COMPARED TO OBINUTUZUMAB AND VENETOCLAX IN PATIENTS WITH HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA
47. CONSOLIDATIVE HCT‐ASCT IS SUPERIOR TO NON‐MYELOABLATIVE CHEMO‐IMMUNOTHERAPY IN NEWLY‐DIAGNOSED PCNSL ‐ UPDATED RESULTS OF THE RANDOMIZED PHASE III MATRIX/IELSG43 TRIAL
48. CLL with Del (17p)/TP53 Mutation
49. „Leukämie-Atlas“ für CLL: Weg zur personalisierten Medizin in der Onkologie
50. A Mixed Analog-Digital Class-D Amplifier with Third-Order Loop Filter for Audio Applications
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.